EverSource Wealth Advisors LLC Purchases 725 Shares of Johnson & Johnson (NYSE:JNJ)

EverSource Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,121 shares of the company’s stock after purchasing an additional 725 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $3,099,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Altman Advisors Inc. purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $1,574,000. Darwin Wealth Management LLC bought a new position in Johnson & Johnson in the third quarter valued at $492,000. Cedar Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 31.3% during the 3rd quarter. Cedar Wealth Management LLC now owns 2,527 shares of the company’s stock valued at $410,000 after buying an additional 602 shares in the last quarter. Grandfield & Dodd LLC lifted its holdings in shares of Johnson & Johnson by 0.9% in the 3rd quarter. Grandfield & Dodd LLC now owns 109,698 shares of the company’s stock worth $17,778,000 after acquiring an additional 993 shares during the last quarter. Finally, Portfolio Design Labs LLC bought a new position in shares of Johnson & Johnson during the third quarter valued at about $2,195,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 22.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Down 0.3 %

NYSE JNJ traded down $0.42 during mid-day trading on Wednesday, reaching $152.58. The stock had a trading volume of 2,468,767 shares, compared to its average volume of 7,004,657. The company has a fifty day moving average price of $160.83 and a 200 day moving average price of $156.19. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The stock has a market cap of $367.35 billion, a PE ratio of 22.14, a price-to-earnings-growth ratio of 2.74 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the prior year, the company posted $2.66 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.25%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Wolfe Research began coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Guggenheim upped their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Royal Bank of Canada raised their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Finally, Morgan Stanley upped their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $175.94.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.